搜索筛选:
搜索耗时5.3405秒,为你在为你在102,285,761篇论文里面共找到 20 篇相符的论文内容
发布年度:
[期刊论文] 作者：Binqing Fu,Haiming Wei,,
来源：Science China(Life Sciences) 年份：2016
During early pregnancy,an orchestrated evolutionary maternal adaption toward tolerance of the semiallogeneic fetus is required to ensure decidualization and ear...
P070 Changes of NK cells in the peripheral blood of patients suffering from rheumatic diseases are p
[会议论文] 作者：Binqing Fu,Haiming Wei,Rui Sun,Zhigang Tian,
来源：第一届世界华人免疫学大会(International Conference on Immunology 2007) 年份：2007
...
[会议论文] 作者：Binqing Fu,Dongyao Wang,Rui Sun,Zhigang Tian,Haiming Wei,
来源：中国免疫学会第十届全国免疫学学术大会 年份：2015
Objective: Type Ⅰ interferons are critical for antiviral immunity and have been widely used in the treatment of HBV and HCV related hepatitis....
BLOCKADE OF B CELLS IN HBV PATIENTS WITH PRE-EXISTING IFNR SIGNALING HAVE IMPROVED EFFECT DURING IFN
[会议论文] 作者：Binqing Fu,Dongyao Wang,Rui Sun,Zhigang Tian,Haiming Wei,
来源：The 1st NI-CMI Joint Conference(第一届CMI-NI免疫学国际研讨会) 年份：2015
...
BLOCKADE OF B CELLS IN HBV PATIENTS WITH PRE-EXISTING IFNR SIGNALING HAVE IMPROVED EFFECT DURING IFN
[会议论文] 作者：Binqing Fu,Dongyao Wang,Rui Sun,Zhigang Tian,Haiming Wei,
来源：The 1st NI-CMI Joint Conference(第一届CMI-NI免疫学国际研讨会) 年份：2015
Type Ⅰ interferons are critical for antiviral immunity and have been widely used in the treatment of HBV and HCV-related hepatitis.However, distinct from HCV, IFN treatments of HBV do not obtain the e...
[会议论文] 作者：Binqing Fu,Yonggang Zhou,Xiang Ni,Zhigang Tian,Haiming Wei,
来源：2016年国际生理学学术大会 年份：2016
Natural killer(NK)cells accumulate at the maternal–foetal interface in large numbers,but their exact roles in successful pregnancy remain poorly defined.Here,we provide evidence that decidual NK cells...
[会议论文] 作者：Binqing Fu,Dongyao Wang,Jiabin Li,Rui Sun,Zhigang Tian,Haiming Wei,
来源：2016年国际树突状细胞研讨会(The 14th International Symposium on Dendriti 年份：2016
...
[会议论文] 作者：Xiaokun Shen,Chuang Guo,Yanyan Liu,Jiabin Li,Rui Sun,Zhigang Tian,Binqing Fu,Haiming Wei,
来源：The 1st NI-CMI Joint Conference(第一届CMI-NI免疫学国际研讨会) 年份：2015
...
[会议论文] 作者：Xiaokun Shen,Yanyan Liu,Chuang Guo,Binqing Fu,Rui Sun,Jiabin Li,Zhigang Tian,Haiming Wei,
来源：The 1st NI-CMI Joint Conference(第一届CMI-NI免疫学国际研讨会) 年份：2015
There is a pressing need to improve therapeutic options for HBV, which is still estimated to cause more than a million deaths a year, from liver cirrhosis and hepatocellular carcinoma.Pegylated interf...
Pegylated Interferon-α Followed by low-dose Interleukin-2 improves the anti-HBV Immunity for HBV non
[会议论文] 作者：Xiaokun Shen,Haiming Wei,Chuang Guo,Dongyao Wang,Rui Sun,Binqing Fu,Yanyan Liu,Jiabin Li,Zhigang Tian,
来源：中国免疫学会第十届全国免疫学学术大会 年份：2015
Background: More than 60% of patients infected with hepatitis B virus (HBV) regarded as NR have a diminished HBV virologic response to standard interferon (...
MicroRNA transcriptomes of distinct human NK cell populations identify miR-362-5p as an essential re
[会议论文] 作者：Fang Ni,Chuang Guo,Rui Sun,Binqing Fu,Yue Yang,Lele Wu,Sitong Ren,Zhigang Tian,Haiming Wei,
来源：第十四届全国肿瘤生物治疗大会 年份：2015
Background: Natural killer (NK) cells are critical effectors in the immune response against malignancy and infection, and microRNAs (miRNAs) play important roles in NK cell biology.However, the microR...
NKp30+ NK cells contribute to HBV control during Pegylated-interferon-alfa-2b therapy of chronic hep
[会议论文] 作者：Xiaokun Shen,Yanyan Liu,Chuang Guo,Binqing Fu,Ying Ye,Rui Sun,Jiabin Li,Zhigang Tian,Haiming Wei,
来源：中国免疫学会第十届全国免疫学学术大会 年份：2015
Approximately 400 million people are chronic HBV surface antigen carriers.There is a pressing need to improve therapeutic options for chronic hepatitis B.Pegylated interferon alpha (Peg-IFN-α) achieve...
Pegylated Interferon-α Followed by low-dose Interleukin-2 improves the anti-HBV Immunity for HBV non
[会议论文] 作者：Dongyao Wang,Binqing Fu,Xiaokun Shen,Yanyan Liu,Chuang Guo,Rui Sun,Jiabin Li,Zhigang Tian,Haiming Wei,
来源：中国免疫学会第十届全国免疫学学术大会 年份：2015
Background: More than 60% of patients infected with hepatitis B virus (HBV) regarded as NR have a diminished HBV virologic response to standard interferon (IFN)-based therapies....
,Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patient
[期刊论文] 作者：Yonggang Zhou,Binqing Fu,Xiaohu Zheng,Dongsheng Wang,Changcheng Zhao,Yingjie Qi,Rui Sun,Zhigang Tian,,
来源：国家科学评论（英文版） 年份：2020
Pathogenic human coronavirus infections,such as severe acute respiratory syndrome CoV (SARS-CoV) and Middle East respiratory syndrome CoV (MERS-CoV),cause high...
[会议论文] 作者：Wenting Li,Xiaokun Shen,Binqing Fu,Chuang Guo,Yanyan Liu,Ying Ye,Rui Sun,Jiabin Li,Zhigang Tian,Haiming,
来源：中国免疫学会第十届全国免疫学学术大会 年份：2015
Natural killer (NK) cells play a key role in host defense against viral infection through their surface activating or inhibitory receptors....
Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, mult
[期刊论文] 作者：Dongsheng Wang,Binqing Fu,Zhen Peng,Dongliang Yang,Mingfeng Han,Min Li,Yun Yang,Tianjun Yang,Liangye,
来源：医学前沿:英文版 年份：2021
Tocilizumab has been reported to attenuate the“cytokine storm”in COVID-19 patients.We attempted to verify the effectiveness and safety of tocilizumab therapy in COVID-19 and identify patients most likely to benefit from this treatment.We ......
[会议论文] 作者：Xiaokun Shen,Chuang Guo,Yongyan Chen,Fang Ni,Rui Sun,Haiming Wei,Binqing Fu,Yanyan Liu,Ying Ye,Jiabin,
来源：The 1st NI-CMI Joint Conference(第一届CMI-NI免疫学国际研讨会) 年份：2015
...
[会议论文] 作者：Chuang Guo,Xiaokun Shen,Binqing Fu,Yanyan Liu,Yongyan Chen,Fang Ni,Ying Ye,Rui Sun,Jiabin Li,Zhigang,
来源：The 1st NI-CMI Joint Conference(第一届CMI-NI免疫学国际研讨会) 年份：2015
Chronic hepatitis B infection is a serious and prevalent health concern worldwide, and the development of effective drugs and strategies to combat this disease is urgently needed.Currently, pegylated...
Transcriptomic characteristics and impaired immune function of patients who retest positive for SARS
[期刊论文] 作者：Dongyao Wang,Dong Wang,Min Huang,Xiaohu Zheng,Yiqing Shen,Binqing Fu,Hong Zhao,Xianxiang Chen,Peng Peng,
来源：分子细胞生物学报（英文版） 年份：2021
Coronavirus disease 2019 (COVID-19),caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection,has become a global public health crisis.Some patients who have recovered from COVID-19 subsequently test positive again fo......
Tocilizumab in patients with moderate or severe COVID-19:a randomized,controlled,open-label,multicen
[期刊论文] 作者：Dongsheng Wang,Binqing Fu,Zhen Peng,Dongliang Yang,Mingfeng Han,Min Li,Yun Yang,Tianjun Yang,Liangye,
来源：医学前沿 年份：2021
Tocilizumab has been reported to attenuate the “cytokine storm” in COVID-19 patients.We attempted to verify the effectiveness and safety of tocilizumab therap...
相关搜索：
